This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations—10 Children and Review of the Literature
Journal of Clinical Immunology Open Access 29 April 2022
-
Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
Bone Marrow Transplantation Open Access 03 July 2021
-
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Leukemia Open Access 09 June 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yeo W, Johnson PJ . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209–220.
Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134: 1470–1481.
Watanabe T, Tanaka Y . Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res 2013; 43: 113–121.
Pardanani A . Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Leukemia 2012; 26: 1449–1451.
Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;; e-pub ahead of print 26 April 2013; doi:10.1038/leu.2013.119.
Shi H, Lu L, Zhang NP, Zhang SC, Shen XZ . Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment. World J Gastroenterol 2012; 18: 3617–3622.
Puro R, Schneider RJ . Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 2007; 81: 7351–7362.
Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012; 5: 552.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.
Wang YH, Fan L, Wang L, Zhang R, Xu J, Fang C et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy. Support Care Cancer 2013; 21: 1265–1271.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Caocci, G., Murgia, F., Podda, L. et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28, 225–227 (2014). https://doi.org/10.1038/leu.2013.235
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.235
This article is cited by
-
Hepatitis B reactivation during ruxolitinib treatment
Annals of Hematology (2022)
-
Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations—10 Children and Review of the Literature
Journal of Clinical Immunology (2022)
-
Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
Bone Marrow Transplantation (2021)
-
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Leukemia (2020)
-
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Annals of Hematology (2020)